Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Abstract:

:All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the prevalence and etiology of and management strategies for TD associated with AAPs. TD prevalence rates varied substantially between studies, with an estimated prevalence of around 20% in patients using AAPs. The risk of TD is lower with AAPs than with typical antipsychotics (TAPs) but remains a problem because AAPs are increasingly being prescribed. Important risk factors associated with TD include the duration of antipsychotic use, age, and ethnicity other than Caucasian. Theories about the etiology of TD include supersensitivity of the dopamine receptors and oxidative stress, but other neurotransmitters and factors are probably involved. Studies concerning the management of TD have considerable methodological limitations. Thus, recommendations for the management of TD are based on a few trials and clinical experience, and no general guidelines for the management of TD can be established. The best management strategy remains prevention. Caution is required when prescribing antipsychotics, and regular screening is needed for early detection of TD. Other strategies may include reducing the AAP dosage, switching to clozapine, or administering vesicular monoamine transporter (VMAT)-2 inhibitors. In severe cases, local injections of botulinum toxin or deep brain stimulation may be considered. More clinical trials in larger samples are needed to gather valid information on the effect of interventions targeting TD.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Stegmayer K,Walther S,van Harten P

doi

10.1007/s40263-018-0494-8

subject

Has Abstract

pub_date

2018-02-01 00:00:00

pages

135-147

issue

2

eissn

1172-7047

issn

1179-1934

pii

10.1007/s40263-018-0494-8

journal_volume

32

pub_type

杂志文章,评审
  • Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

    abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115110-00004

    authors: Lacour M,Sterkers O

    更新日期:2001-01-01 00:00:00

  • Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

    abstract::Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721100-00002

    authors: Mocellin R,Walterfang M,Velakoulis D

    更新日期:2007-01-01 00:00:00

  • The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

    abstract::The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0517-5

    authors: Damkier P,Videbech P

    更新日期:2018-04-01 00:00:00

  • Role of the melatonin system in the control of sleep: therapeutic implications.

    abstract::The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721120-00004

    authors: Pandi-Perumal SR,Srinivasan V,Spence DW,Cardinali DP

    更新日期:2007-01-01 00:00:00

  • Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

    abstract:BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-014-0191-1

    authors: Shcherbakova N,Rascati K,Brown C,Lawson K,Novak S,Richards KM,Yoder L

    更新日期:2014-11-01 00:00:00

  • Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.

    abstract:INTRODUCTION:Cognitive impairment is prevalent and debilitating among persons with multiple sclerosis (MS). While many pharmacologic treatments have shown good efficacy in reducing clinical relapses, brain lesions, and improving certain physical symptoms, their efficacy for improving cognitive function is not well unde...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00734-4

    authors: Chen MH,Goverover Y,Genova HM,DeLuca J

    更新日期:2020-06-01 00:00:00

  • Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

    abstract:OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200721010-00006

    authors: Dodick DW,Sandrini G,Williams P

    更新日期:2007-01-01 00:00:00

  • Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

    abstract:BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...

    journal_title:CNS drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s40263-018-0586-5

    authors: Hobart J,Ziemssen T,Feys P,Linnebank M,Goodman AD,Farrell R,Hupperts R,Blight AR,Englishby V,McNeill M,Chang I,Lima G,Elkins J,ENHANCE study investigators.

    更新日期:2019-01-01 00:00:00

  • Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

    abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923060-00006

    authors: Carter NJ,McCormack PL

    更新日期:2009-01-01 00:00:00

  • Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

    abstract::The kynurenine pathway constitutes the main route of tryptophan degradation and generates the production of several neuroactive compounds; quinolinic acid is an excitotoxic NMDA receptor agonist, 3-hydroxykynurenine is a free-radical generator and kynurenic acid (KYNA) is an antagonist at glutamate and nicotinic recep...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923020-00001

    authors: Erhardt S,Olsson SK,Engberg G

    更新日期:2009-01-01 00:00:00

  • Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

    abstract::Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0075-9

    authors: Keating GM

    更新日期:2013-06-01 00:00:00

  • Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

    abstract::The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00756-y

    authors: Zheng C,Kar I,Chen CK,Sau C,Woodson S,Serra A,Abboud H

    更新日期:2020-09-01 00:00:00

  • Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations.

    abstract::Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-017-0427-y

    authors: Parsons C,van der Steen JT

    更新日期:2017-06-01 00:00:00

  • Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.

    abstract::Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204710-000000000-00000

    authors: Keating GM,Lyseng-Williamson KA

    更新日期:2010-09-01 00:00:00

  • Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?

    abstract:BACKGROUND AND OBJECTIVE:Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used t...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-017-0462-8

    authors: Swallow E,Fang A,Signorovitch J,Plumb J,Borghs S

    更新日期:2017-10-01 00:00:00

  • Treatment of epileptic encephalopathies.

    abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0041-6

    authors: McTague A,Cross JH

    更新日期:2013-03-01 00:00:00

  • Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment.

    abstract::Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216110-00003

    authors: Warnock JJ

    更新日期:2002-01-01 00:00:00

  • Pharmacological interventions for the treatment of smokeless tobacco use.

    abstract::Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11598450-000000000-00000

    authors: Ebbert JO,Fagerstrom K

    更新日期:2012-01-01 00:00:00

  • Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.

    abstract::Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0438-8

    authors: Cather C,Pachas GN,Cieslak KM,Evins AE

    更新日期:2017-06-01 00:00:00

  • Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

    abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00766-w

    authors: Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

    更新日期:2020-11-01 00:00:00

  • Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.

    abstract:BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40263-016-0323-x

    authors: Bushe C,Sobanski E,Coghill D,Berggren L,De Bruyckere K,Leppämäki S

    更新日期:2016-04-01 00:00:00

  • Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents.

    abstract::Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...

    journal_title:CNS drugs

    pub_type: 评论,杂志文章

    doi:10.2165/00023210-200822030-00006

    authors: Scott LJ,Dhillon S

    更新日期:2008-01-01 00:00:00

  • Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine.

    abstract::Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0186-y

    authors: Garnock-Jones KP

    更新日期:2014-08-01 00:00:00

  • Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

    abstract::Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0307-2

    authors: Logallo N,Kvistad CE,Nacu A,Thomassen L

    更新日期:2016-02-01 00:00:00

  • Subacute sclerosing panencephalitis : diagnosis and drug treatment options.

    abstract::Subacute sclerosing panencephalitis (SSPE) is a chronic progressive, usually fatal disease of uncertain pathogenesis that is associated with the presence of mutant measles virus in the CNS. The diagnosis is based on clinical criteria and an elevated titre of measles antibodies in the CSF. Electroencephalography, imagi...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199707020-00003

    authors: Anlar B

    更新日期:1997-02-01 00:00:00

  • Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

    abstract::Schizophrenia is a long-term psychiatric disorder that impacts important mental functions and requires indefinite treatment, as well as psychosocial and economic support. The introduction of chlorpromazine, the first antipsychotic, and the subsequent development of a long list of similar dopamine-blocking antipsychoti...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0588-3

    authors: Awad AG

    更新日期:2019-01-01 00:00:00

  • Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation.

    abstract::Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0250-2

    authors: Mackie S,Winkelman JW

    更新日期:2015-05-01 00:00:00

  • The new generation of GABA enhancers. Potential in the treatment of epilepsy.

    abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115050-00001

    authors: Czuczwar SJ,Patsalos PN

    更新日期:2001-01-01 00:00:00

  • Guide to anaesthetic selection for electroconvulsive therapy.

    abstract::Electroconvulsive therapy (ECT) is used in the treatment of severe psychiatric disorders. It involves the induction of a seizure for therapeutic purposes by the administration of a variable-frequency electrical stimulus via electrodes applied to the scalp. The original application of ECT in non-anaesthetised patients ...

    journal_title:CNS drugs

    pub_type: 指南,杂志文章,实务指引,评审

    doi:10.2165/00023210-200519090-00002

    authors: Wagner KJ,Möllenberg O,Rentrop M,Werner C,Kochs EF

    更新日期:2005-01-01 00:00:00

  • When should triptans be taken during a migraine attack?

    abstract::The common strategy to treat a migraine attack as soon as it begins, made for classical acute antimigraine treatments such as ergotamine and analgesics, has not been transposed to the triptans. The recommendation to delay triptan intake until headache intensity is at least moderate is merely a habit generated by the p...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200115080-00001

    authors: Schoenen J

    更新日期:2001-01-01 00:00:00